PRINCETON, N.J., March 21, 2011 /PRNewswire/ — PharmaNet
Development Group, Inc., a leading provider of drug development
services to the pharmaceutical, biotechnology, generic drug and
medical device industries, announces its participation at the 19th
Annual Partnerships in Clinical Trials Conference in Phoenix,
Arizona from March 30 to April 1. PharmaNet and industry experts
will discuss pertinent industry topics, including:
Thursday March 31
Impact of Reform on Biosimilar Drug Development
Dalvir Gill, Ph.D., President, Late Stage Development, PharmaNet
and Greg Skalicky, Senior Vice President, Worldwide Business
Development, PharmaNet
Proactive GCP Compliance and Quality Management
Systems
Jeffrey P. McMullen, CEO, PharmaNet and John W. Hubbard, Ph.D.,
FCP, Senior Vice President Worldwide Head, Development Operations,
Pfizer
Assess the Impact of Industry Consolidation on Change
Management and Your Outsourcing Operational Model
Marisa Bower, Senior Director, Business Development,
PharmaNet
Outsourcing Phase IV Observational Studies: A Different
Animal?
Jeffrey Trotter, Executive Vice President, Phase IV Development,
PharmaNet
Friday April 1
Challenges and Opportunities in the Global Arena in Pediatric
Drug Development
Philippa Smit-Marshall, MBChB, FFPM, FICR, Vice President and
General Manager of Pediatrics & Medical Sciences, PharmaNet;
and Diane Hoffman, Associate Director, Clinical Research Pediatric
Group, Johnson & Johnson
Conference attendees can learn more about PharmaNet’s
capabilities by visiting booth 901 in the exhibition hall where an
international team of representatives will be available to discuss
PharmaNet’s expertise in helping clients reach their goal of
delivering safe and effective therapeutics to patients.
About PharmaNet
PharmaNet, a recognized leader of global drug
‘/>”/>
